SARS-CoV-2's Variants of Concern: A Brief Characterization.
COVID-19
COVID-19 vaccination
SARS-COV-2 variants
SARS-CoV-2
viral immune escape
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
12
2021
accepted:
13
06
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disclose the variants of concern (VOC) including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1), Delta (B.1.617.2), and Omicron (B.1.1.529). Its spike protein (S) present on the surface of the virus is recognized by the host cell receptor, the angiotensin-2 converting enzyme (ACE2) which promotes their entry into the cell. The mutations presented by VOCs are found in RBD and the N-terminal region of S protein. Therefore, mutations occurring in RBD can modify the biological and immunogenic characteristics of the virus, such as modifying the spike affinity for ACE2, increasing the virus transmissibility, or conferring the ability to escape the immune responses. The raise of a potential new SARS-CoV-2 variant capable of evading the host defenses at the same time maintaining its fitness justifies the importance of continued genetic monitoring of the pandemic coronavirus.
Identifiants
pubmed: 35958548
doi: 10.3389/fimmu.2022.834098
pmc: PMC9361785
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
834098Informations de copyright
Copyright © 2022 Scovino, Dahab, Vieira, Freire-de-Lima, Freire-de-Lima and Morrot.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2021 Oct 6;12(1):5861
pubmed: 34615860
Elife. 2021 Aug 20;10:
pubmed: 34414884
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Med. 2021 Apr;27(4):571-572
pubmed: 33649495
Infect Dis (Lond). 2021 Jan;53(1):1-8
pubmed: 33043748
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nature. 2022 Mar;603(7902):693-699
pubmed: 35062016
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Cell Host Microbe. 2021 Jul 14;29(7):1093-1110
pubmed: 34242582
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nat Commun. 2021 Oct 20;12(1):6103
pubmed: 34671049
Cell Rep. 2021 Nov 2;37(5):109928
pubmed: 34706271
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Immunol Res. 2022 Apr;70(2):143-151
pubmed: 34782989
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Microb Pathog. 2021 May;154:104831
pubmed: 33727169
Bol Med Hosp Infant Mex. 2020;77(5):262-273
pubmed: 33064680
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Viruses. 2021 Oct 22;13(11):
pubmed: 34834934
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Nat Commun. 2022 Jan 24;13(1):460
pubmed: 35075154
Allergy. 2020 Oct;75(10):2445-2476
pubmed: 32584441
Sci Rep. 2022 Jan 21;12(1):1128
pubmed: 35064154
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Lancet Reg Health Am. 2021 Sep;1:100025
pubmed: 34386791
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
Biochem Biophys Res Commun. 2022 Jan 29;590:34-41
pubmed: 34968782
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Lancet Infect Dis. 2021 Aug;21(8):1071-1072
pubmed: 34051887
Lancet Microbe. 2021 Oct;2(10):e527-e535
pubmed: 34258603
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Nat Rev Microbiol. 2008 Feb;6(2):143-55
pubmed: 18197170
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Signal Transduct Target Ther. 2021 Sep 27;6(1):349
pubmed: 34580279
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):
pubmed: 34140350
PLoS Pathog. 2021 Aug 5;17(8):e1009772
pubmed: 34352039
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Vaccine. 2022 May 3;40(20):2869-2874
pubmed: 35400561
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Commun Med (Lond). 2022 Jun 29;2:76
pubmed: 35784447
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Vaccines (Basel). 2021 Dec 25;10(1):
pubmed: 35062684
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279